Summary

Eligibility
for people ages 8 years and up (full criteria)
Healthy Volunteers
healthy people welcome
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Matthew Bucknor (ucsf)
Headshot of Matthew Bucknor
Matthew Bucknor

Description

Summary

Osteoid osteomas are painful, benign bone tumors that occur most frequently in young males between ages 10 and 20 years. The goal of the proposed study is based on the premise that MRgFUS is noninferior to CT-guided radiofrequency ablation (CTgRFA), in terms of pain reduction following treatment of osteoid osteomas, and offers possible improvements with regards to 1) post-procedural pain, 2) clinical resource utilization, 3) patient experience, and/or 4) adverse events. The data from the current study would provide clinicians important information in deciding between treatment options for ablation of osteoid osteomas.

Official Title

Phase III Study to Compare the Effectiveness of Magnetic Resonance Guided Focused Ultrasound with Computed Tomography Guided Radiofrequency Ablation for Treatment of Osteoid Osteomas

Keywords

Osteoid Osteoma, Osteoma, MRgFUS, CTgRFA

Eligibility

Locations

  • UCSF Imaging Center accepting new patients
    San Francisco California 94107 United States
  • Stanford Medical Center accepting new patients
    Palo Alto California 94305 United States
  • Mayo Clinic accepting new patients
    Rochester Minnesota 55905 United States

Lead Scientist at University of California Health

  • Matthew Bucknor (ucsf)
    Matthew Bucknor, MD, MFA is a musculoskeletal radiologist and the Associate Chair for Wellbeing and Professional Climate in the UCSF Department of Radiology and Biomedical Imaging. He also serves as Executive Sponsor of Differences Matter, a multi-year School of Medicine initiative designed to promote belonging at UCSF.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Matthew Bucknor
ID
NCT02923011
Phase
Phase 3 Osteoid Osteoma Research Study
Study Type
Interventional
Participants
Expecting 56 study participants
Last Updated